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ABSTRACT: The chemical modification of proteins is at the
frontier of developments in biological imaging and biopharma-
ceutics. With the advent of more sensitive and higher resolution
imaging techniques, researchers increasingly rely on the
functionalization of proteins to enable these techniques to
capture cellular processes. For biopharmaceutical therapies,
chemically modified proteins, for example, antibody-drug
conjugates (ADCs) offer the possibility of more tailored
treatments for the disease with lower toxicities than traditional
small molecule therapies. However, relatively little consideration
is paid to how chemical modifications impact protein−protein interactions and solution stability. Using human γD-crystallin as a
model, we demonstrate that chemical modification of the protein surface alters protein−protein interactions, which can result in
lower solubility depending on the chemical nature of the modifier and the position on the protein where the modification is
made. Understanding these effects is essential to ensure that modifying proteins effectively occurs with minimum self-
association and that studies carried out using labeled proteins accurately reflect those of unmodified proteins.
■ INTRODUCTION
Of the 22 biologically active proteinogenic amino acids, 15 are
subject to diversification via posttranslational modification
(PTM; there are no known modifications of Leu, Ile, Val, Ala,
Phe, Sec, and Pyl).1 In almost all cases, naturally occurring
PTMs are crucial for the function and structure of proteins.2−4
The artificial chemical modification of a protein surface
(which will be referred to here simply as “chemical
modification”) was first reported in 1904 and has, since then,
been a mainstay in the study of proteins.5 Covalent
posttranslational modifications (PTMs) are chemical mod-
ifications of proteins that occur either in vivo or in vitro after
their biosynthesis and serve to change the structure or function
of the protein by means of covalent attachment of a functional
group or protein (such as ubiquitination), proteolytic (or less
commonly, autocatalytic) cleavage, or degradation.1,6 In
addition to ubiquitination, common naturally occurring
PTMs include acetylation, acylation, ADP-ribosylation, lip-
idation, amidation, γ-carboxylation, β-hydroxylation, disulfide
bond formation, methylation, glycosylation, phosphorylation,
proteolytic processing, and sulfation.2,7,8 Given the diversity of
structure and function imposed on proteins as a result of
naturally occurring PTMs, the ability to chemically modify
proteins by artificial means is highly attractive.6 The chemical
modification of a protein surface is an important mechanism
for altering protein function and is commonly employed for
protein tracking using fluorophores in biological systems and is
in widespread use in the biopharmaceutical industry to alter or
enhance the function of protein biotherapeutics using either
natural or synthetic covalent PTMs (e.g., via glycosylation and
PEGylation).7,9,10 PEGylation of a protein has also been
successfully achieved via noncovalent modification of a fucose-
binding lectin with a fucose-capped PEG.11 More recently,
chemical modification has been employed in the development
of antibody-drug conjugates (ADCs) for the targeted treat-
ment of malignant tumor cells.12−15 These chemical
modifications have led to the development of a diverse range
of proteins with functionalities beyond their initial capabilities.
As a result, understanding, quantifying, and predicting how
modifications made to the surface of a protein affect its
behavior and stability are required.
Lysine (Lys, K) and cysteine (Cys, C) are the amino acids
most often used for chemical modification13,16 owing to their
inherent nucleophilic character.6,9,17 Lysine is one of the most
abundant amino acids in proteins, and there are many
established protocols to preferentially chemically modify the
amine of its side chain, which is typically the most nucleophilic
amine on a protein surface.16−19 Preferential modification of
Lys requires the use of “harder” nucleophiles such as activated
esters, sulfonyl chlorides, and isothiocyanates or modification
can be achieved through reductive alkylation using aldehydes
in the presence of cyanoborohydride.9 The abundance of Lys
can lead to heterogeneous mixtures of the modified protein,
which may be useful in some applications, where multiple
conjugates are required but undesirable in others such as the
development of some biopharmaceutics where a more
homogenous mixture is preferred.9 Cysteine is regarded as
the most important naturally occurring amino acid for
chemical modification because in addition to its highly
nucleophilic nature (it is much more nucleophilic than Lys),
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it has a low abundance (<2%), which allows for chemical
modification with a greater degree of specificity.9,16,19,20 There
are a number of electrophiles available for the specific labeling
of Cys residues such as α-halocarbonyls, iodoacetamides, and
maleimides, with maleimides prevailing as the most commer-
cialized and widely used derivative for Cys modification due to
ease of use and straightforward synthesis.9 Indeed, a
selenocysteine residue, which is more nucleophilic than Cys,
can be inserted into a protein for highly specific modification
also using maleimide derivatives.21
Other amino acids can be chemically modified but can be
more synthetically challenging to achieve.16 Tyrosine (Tyr)
and tryptophan (Trp) are rarely found on the surface of a
protein (due to their hydrophobic nature), which has made
them the subject of focus as sites for chemical modification
because single-site modification is advantageous6,22 The
modification of Tyr and Trp is generally performed using
water-soluble transition metal catalysis.23 Trp has the lowest
natural abundance of all the canonical amino acids, which can
allow for Trp modification specificity provided the protein
being modified has no surface-bound Tyr residues. Chemical
modification of histidine (His), arginine (Arg), glutamic acid
(Glu), and aspartic acid (Asp) is also possible as each has a
nucleophilic residue that can be used as a site for modification
but their use is much rarer than modifications of Lys, Cys, Tyr,
and Trp.17 His is a target for nucleophilic attack and is highly
selective toward vinyl sulfone, which allows for the site-specific
labeling with molecules containing a vinyl sulfone group as an
acetylating agent.24 While Arg has a similar abundance to Lys,
it has a lower tendency to be found on the surface of the
protein, which makes it more favorable for site-specific
modification.25 Specific modification of Arg involves the
formation of a pyrimidine ring using two out of the three
nitrogen atoms found in its side chain.26 Although it is highly
selective, modification of Arg requires a 14 day reaction time,
which may make it an unsuitable choice of site for some
studies that require specificity and a short reaction time.
Modification of the carboxylate groups in Glu and Asp involves
amidation using ethylenediamine.27 However, ethylenediamine
indiscriminately labels both Glu and Asp, which make these
sites unfavorable, as sites for modification. Methionine (Met)
is the only other sulfur-containing proteinogenic amino acid.
Though it is similar to Cys in terms of its natural abundance, it
does not share the same popularity as a site of modification
due to its weak nucleophilicity.28 However, redox-based
reagents are emerging as a strategy for chemoselective Met
modification.28 An extensive review of synthetic routes for
selective proteinogenic amino acid modification has been
recently published.29 In addition to modification of proteino-
genic amino acids, there has been recent interest in the
insertion of noncanonical amino acids for use as sites for
modification to enhance site selectivity.30,31
The surface of a protein is inherently anisotropic as a result
of the varying amino acid side chains on the protein surface.32
The interactions of amino acid side chains determine the
specific biological, chemical, and technological functions of
each protein.32,33 Proteins in solution can undergo a number of
different phase transitions to form condensed phases and
states: reversible or irreversible solid−liquid phase separation
leading to the formation of amorphous or ordered solids or less
frequently, liquid−liquid phase separation (LLPS), also known
as coacervation, whereby two metastable liquid phases are
formed, one protein rich and one protein poor.34 LLPS is also
observed in some colloidal systems and is characteristic of
short-range (less than a quarter of the diameter of the particle)
attractive interactions.34,35 Understanding the fundamental
mechanisms, which determine protein phase behavior, is a key
requirement in the biopharmaceutical industry.36 Protein
phase diagrams are used to predict the physical state of a
protein for a given set of conditions across a range of volume
fractions (e.g., temperature, pressure, salt concentration, and
pH)35,37,38 and are a good measure of the strength of protein
interactions.37 Changes in the protein environment, such as
varying ionic strength or pH,33 the introduction of another
protein type,39,40 the introduction of a mutation,41,42 or a
chemical modification of the protein surface43 can change its
phase diagram. Because protein solution stability is intrinsically
linked to the strength of its interaction potential, phase
diagrams are a useful way of understanding, measuring, and
predicting the effect modifications to the surface of a protein
have on its behavior in solution.
The lens crystallins are a family of proteins that undergo
LLPS at physiological pH. These highly soluble proteins are
essential for vision and are found in the nucleus and cortex of
the eye lens and remain soluble, in many cases over a lifetime
to maintain lens transparency.44 Human γD-crystallin (HGD)
is soluble at concentrations in excess of 400 mg mL−1.45,46
HGD, which has a near-neutral pI (7.1), exhibits short-ranged
attractive interactions and therefore can undergo LLPS at
physiological pH. Cataract is the leading cause of blindness
worldwide and results in a loss of transparency due to
increased light scattering within the eye lens.44,47 Congenital
(or childhood) cataracts arising from single amino acid
mutations in the sequence of HGD have been studied
extensively.41,48−56 These point mutations lead to a decrease
in lens protein solubility and lens transparency as a result of
increased light scattering and can lead to blindness.
Surprisingly, given the prevalence of Lys, which can account
for as much as 10% of the amino acids in a typical protein,18
HGD contains only a single Lys residue located at position 2.
Despite it having six unpaired Cys residues, only one, at
position 110, is surface-exposed.41,57 The surface exposure of a
single Lys and Cys residues in HGD coupled with its stability
at high concentrations (>400 mg mL−1) and its ability to
undergo LLPS make HGD an ideal model protein to assess
how chemical modification of the protein surface impacts on
its solution behavior. Because we have explicit control over the
number of labeling sites on the protein surface, any changes in
the temperature at which LLPS occurs are indicative of
changes in the net attractive protein−protein interactions on
the protein surface due to the introduction of further chemical
anisotropy to the protein surface by covalent attachment of a
specific molecule. We have already demonstrated using a
combination of experiments and coarse grained simulations43
that fluorescently labeling HGD using small molecule
fluorophores increases the temperature at which LLPS occurs
(Tph) due to an increase in net attraction in the system. Small
molecule fluorophores are significantly larger and inherently
more hydrophobic in nature (given their aromatic structures)
than any naturally occurring amino acid, and we hypothezised
based on the experimental data that the decrease in protein
stability was due to the addition of a large attractive patch on
the protein surface due to the hydrophobicity of the
fluorophore. To test this hypothesis, we have labeled the
protein at the same amino acid residues with a hydrophilic tag,
biotin. If the change in solution behavior observed in the
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presence of a fluorophore was due to its hydrophobicity, then
modification of the same amino acids with a hydrophilic
molecule should restore (or eliminate) any decrease in
solubility observed. Hence, based on the nature of the
molecule used to adapt a protein and the position it is
located, chemical modification can be used to modulate
protein−protein interactions where this is required (for
example in protein crystallization) or decrease the impact of
a necessary but problematic modification (e.g., by increasing
hydrophilicity or changing its position on the protein) to
improve solubility.
■ EXPERIMENTAL SECTION
Preparation of Materials. Analytical grade glacial acetic
acid, sodium hydroxide (NaOH), sodium chloride, sodium
dihydrogen orthophosphate dihydrate, dibasic sodium phos-
phate heptahydrate, hydrochloric acid (HCl), sodium azide,
LB Agar, LB Broth, isopropyl β-D-1-thiogalactopyranoside
(IPTG), magnesium sulfate heptahydrate, ethylenediaminete-
traacetic acid (EDTA), and dithiothreitol (DTT) were
purchased from Fisher Scientific (UK). Lysozyme and Tris
HCl were purchased from Merck Millipore (Ireland). Protease
inhibitor cocktail tablets were purchased from Roche
Diagnostics (USA). Buffers were prepared using ultrapure
(Milli-Q) water, and pH values were adjusted using
concentrated NaOH or HCl. Buffers were filtered through a
0.45 μm MillexHV syringe filter or nylon membrane filter
(Merck Millipore, Ireland) before use. Amicon Ultra 4 mL
centrifugal filters were used for buffer exchange (Merck
Millipore, Ireland).
Expression, Purification, and Characterization of
HGD. HGD was prepared by recombinant methods as
previously described.41 HGD protein purity was confirmed at
>98% by SDS-PAGE and size exclusion HPLC. The molecular
weight of HGD was confirmed to be 20,608 ± 1 Da by intact
molecular weight analysis using electrospray ionization mass
spectrometry, carried out in “FingerPrints” Proteomics Facility
at the University of Dundee, Scotland, UK, and is in agreement
with previously published data.41 Protein concentration in mg
mL−1 was determined spectroscopically using a mass extinction
coefficient equal to 2.09 mg−1 mL cm−1 for HGD.39 The
volume fraction, ϕ, was calculated using the expression ϕ = cν,
where c is the protein concentration in mg mL−1, and v is the
partial specific value in mL mg−1 equal to 7.1 ± 0.1 × 10−4 for
the γ crystallins.58
Chemical Modification of Lys-2 and Cys-110 Amino
Acid Residues. Amine modification of Lys-2 in HGD was
carried out after purification using EZ-Link NHS-PEG4-Biotin
(Pierce Biotechnology, USA) as per supplied instructions.
Thiol modification of Cys-110 was carried out after
purification using EZ-Link Maleimide-PEG2-Biotin (Pierce
Biotechnology, USA). Interprotein disulfide bonds were
reduced using 2-mercaptoethylamine-HCl (Pierce Biotechnol-
ogy, USA) as per supplied instructions before modification.
Biotinylated proteins were quantified using a Pierce Biotin
Quantitation Kit (Thermo Scientific, USA) as per supplied
instructions. Fluorescence measurements were performed
using a Molecular Devices M2e spectrofluorometer, and
spectral data were replotted and analyzed using OriginPro
2016 data analysis software.
Circular Dichroism Spectroscopy. Circular dichroism
(CD) spectra were recorded at near- and far-UV wavelengths
for samples of unmodified HGD, amine modified HGD (xm =
0.86), and thiol modified HGD (xm = 0.88) at a concentration
of 0.1 mg mL−1 in 0.1 M sodium phosphate buffer at pH 7.
Measurements were performed using a JASCO J-810
spectropolarimeter (Institute of Molecular, Cell, and Systems
Biology, College of Medical, Veterinary, and Life Sciences,
University of Glasgow, Scotland, UK). Spectral data were
plotted using OriginPro 2016 data analysis software.
Liquid−Liquid Phase Separation Measurements.
Liquid−liquid coexistence curves were measured using a
method previously outlined59 for unmodified HGD, mixtures
of unmodified HGD and amine modified HGD, and mixtures
of unmodified HGD and thiol modified HGD in 0.1 M sodium
phosphate buffer at pH 7. A Perkin Elmer Lambda 35 UV−vis
spectrophotometer and UV Win Lab − Timedrive Lambda 35
associated software were used to measure the percentage
transmission of light at λ = 600 nm through a Hellma quartz
cuvette with a pathlength of 1 cm. A Thermo Scientific K10
water bath attached to a Thermo Scientific D10 temperature
control was used for temperature regulation. The system
temperature was monitored using an Omega HH509R
thermocouple. OriginPro 2016 was used to construct phase
diagrams for each mixture. LLPS was induced for a mixture of
unmodified and thiol modified HGD (xm = 0.89) in a Thermo
Scientific Heraeus Multifuge 3SR+ temperature controlled
centrifuge using a method described previously to determine
modified protein partitioning.60 The volume fraction and
fraction of biotinylated protein for each phase were quantified
as before using a Biotin Quantitation Kit.
■ RESULTS AND DISCUSSION
Two forms of chemically modified HGD were used to
investigate the phase behavior of mixtures of modified and
unmodified protein: HGD chemically modified with
PEGylated biotin at the Lys-2 position and at the Cys-110
position. The sites used for chemical modification (Lys-2 and
Cys-110) are shown in Figure 1.
The liquid−liquid phase separation (LLPS) temperature
(Tph) for each modified protein in mixtures with native protein
was used to quantify the change in net interaction potential
between proteins for mixtures of modified and unmodified
proteins.
Chemical modification of Lys-2 and Cys-110 using
PEGylated biotin. PEGylated biotin was used to chemically
modify sites 2 and 110 of HGD. Biotin is a vitamin (also
known as vitamin H, vitamin B7, or coenzyme R) with a valeric
acid side chain that allows derivatization of this moiety for
enhanced functionality. It is a relatively small molecule with a
molecular weight of 244.3 g mol−1 compared to the molecular
Figure 1. Topological rendering of HGD showing the locations of
modified sites, Lys-2 (purple) and Cys-110 (yellow).
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weight of HGD, which is approximately 21 kDa. While biotin
itself is water-soluble, its derivatization with a PEG linker is
intended to enhance the hydrophilicity of the biotin molecule
by increasing the solvation shell around the molecule.
Separate chemical modifications of HGD were carried out to
create two forms of modified protein: modification of HGD at
the Lys-2 position and modification of a free thiol at the Cys-
110 position. Tph was measured up to a volume fraction of
∼0.14 for mixtures of Lys-2 modified HGD across two
modified protein compositions. Separately, Tph was also
measured up to a volume fraction of ∼0.07 for two different
Cys-110 modified protein compositions. The liquid−liquid
coexistence curves for these mixtures are shown in Figure 2.
The lower concentration limit for the cysteine-modified
protein was necessary because modification at this site reduced
solubility and precipitation of protein begins to occur at higher
volume fractions.
The LLPS data for unmodified HGD and each of the
mixtures with modified protein were fitted using eq 158
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where ϕ and ϕc are the volume fraction and critical volume
fraction, respectively (where the partial specific volume, ν, of
HGD and its modified forms is taken to be 7.1 ± 0.1 × 10−4
mL mg−1), A is a parameter related to the width of the
coexistence curve, T and Tc are the phase separation
temperature and critical temperature, respectively, and β is
an exponent term for the three-dimensional Ising model equal
to 0.325. The critical volume fraction, ϕc, was taken to equal
0.21, a value consistent with ϕc for all gamma crystallins.
61 The
estimated values for Tc, ΔTc, and A are given in Table 1 for
each composition of chemically modified protein.
The change in Tph after modifying the thiol at site 110 is
significantly greater than modifying the primary amine at the
site 2. The site-specific differences on the effect of a
modification is consistent with our previous work, which also
indicated that HGD chemically modified at Lys-2 had less
impact than labeling at Cys-110.43 When fluorescently labeled
protein was present in mixtures with unlabeled HGD at
protein compositions between 0.0001 and 0.01 (partial data is
shown in Figure 3), an increase in Tph with an increase in the
proportion of modified protein was observed. The proportion
of labeled protein that was required to increase Tph was
substantially lower for protein modified at the Cys position (by
a factor of ∼50).
While there is very little change in Tph for HGD modified
with PEGylated biotin at the amine position (i.e., ΔTc is within
the maximum experimental error in measurements of Tph),
there is a substantial increase in Tph with increasing
proportions of HGD modified with PEGylated biotin at the
thiol position. The range of the protein−protein interactions is
related to the width of the liquid−liquid coexistence curve
where a decrease in the coexistence curve width is indicative of
an increase in the interaction range of the protein.61−63
However, there is no change in the width of the coexistence
curve for HGD modified with PEGylated biotin (parameter A
in eq 1, see Table 1). This suggests that the increased net
attraction as indicated by the increase in Tph is not due to an
increase in the range of the attraction, unlike the observations
for proteins modified with a fluorescent tag in our earlier
work.43 Figure 3 shows partial coexistence curves for HGD in
mixtures with fluorescently labeled HGD modified at the
amine position (NH) and thiol position (SH) where an
increase in Tph was accompanied by a decrease in curve width.
For biotinylated protein, we need to add a significantly higher
fraction of modified protein required to induce a change in Tph
of similar magnitude (xm = 0.0001 for fluorescently labeled
HGD vs xm = 0.89 for HGD chemically modified with
PEGylated biotin). Hence, there are notable differences
between this and the case of fluorescently labeled proteins.
Electrostatic interprotein interactions between charged
groups on the protein surface contribute to its solubility.64
The pI of HGD (pI = 7.1) is almost at physiological pH and is
very close to the working pH used in the data presented here.
Lysine (along with histidine and arginine) is one of three
positively charged amino acid residues at neutral pH (pH 7).
The modification of Lys-2 by covalent attachment of the
Figure 2. Liquid−liquid coexistence curves for unmodified HGD
(black) and (A) protein mixtures in aqueous solution of unmodified
and amine modified (blue) and (B) thiol modified (pink) HGD with
increasing modified protein compositions (xm). Panel A indicates
liquid−liquid coexistence curves for protein mixtures in aqueous
solution of unmodified HGD and HGD amine modified with PEG4-
Biotin. Panel B shows liquid−liquid coexistence curves for unmodified
HGD and binary protein mixtures in aqueous solution of unmodified
HGD and HGD thiol modified using PEG2-Biotin.
Table 1. Values for Estimated Changes in Critical
Temperature to the Nearest Kelvin, K (ΔTc) with Respect
to Unmodified HGD Using eq 1 for Each Binary Protein
Mixture in Aqueous Solution
modified protein
Tc
(K)
ΔTc
(K) A
unmodified HGD (xm = 0.00) 277 2.6
HGD amine modified with PEG4-Biotin
(xm = 0.62)
278 1 2.6
HGD amine modified with PEG4-Biotin
(xm = 0.86)
279 2 2.6
HGD thiol modified with PEG2-Biotin (xm = 0.47) 283 6 2.6
HGD thiol modified with PEG2-Biotin (xm = 0.89) 287 10 2.6
Figure 3. Liquid−liquid coexistence curves for HGD (black) and
HGD chemically modified via fluorescent labeling of a primary amine
(blue) and thiol (pink).
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PEGylated biotin thus removes one positive charge from the
protein surface and results in a protein with a net negative
charge. This change in charge may be a contributing factor as
to why the increase in net attraction (as indicated by the lower
change in Tph) is not as substantial as the increase in Tph for
HGD modified at Cys-110 with PEGylated biotin. Because the
structures of the small molecule fluorescent dyes previously
used for the specific labeling of HGD are proprietary, it is not
possible to comment on how this affected the electrostatic
contribution of the net interaction potential. Fluorescein
isothiocyanate, FITC, which has a partial negative charge at
neutral pH, can modify both primary and secondary amines. As
a result, HGD labeled with FITC will carry a net negative
charge, which should contribute to its solution stability. A
mixture of HGD and HGD fluorescently labeled with FITC
(xL = 0.0002) led to an increase in a Tph of 20 K. This suggests
that the hydrophobicity rather than electrostatics contributed
more to the net interaction potential in that case.
Chemically Modified HGD Partitioning. A mixture of
unmodified and modified HGD biotinylated at the Cys-110
position (xm = 0.89) was cooled to below its Tph to induce
LLPS and centrifuged to macroscopically separate the dilute
and dense liquid phases (Figure 4). The modified protein
composition was determined for each phase following the
complete separation of the dense and dilute phases and found
to be 0.80 in the dilute phase and 0.87 in the dense phase. The
preferential partitioning of the more attractive protein (i.e., the
modified HGD) into the dense protein phase is consistent with
previously published data using fluorescently labeled HGD
where the majority of the chemically modified protein
partitioned into the dense protein phase.39,43
Circular Dichroism. A structural or conformational change
as a result of unfolding can cause an increase in the net
attraction of a protein due to the exposure of hydrophobic
residues. To determine if this was the case for both the amine
and thiol modified proteins, near-and far-ultraviolet (UV)
circular dichroism (CD) spectroscopies were used to assess the
impact of chemically modifying HGD with PEGylated biotin
on its respective tertiary and secondary structures (Figure 5).
The spectral data indicate that there was no significant
change in the tertiary and secondary structures of the modified
protein relative to the unmodified protein thus that a structural
or conformational change is not responsible for the net
increase in attraction of the modified protein, indicated by the
increase in Tph. This data is consistent with our previously
published CD data for HGD chemically modified with small
molecule fluorescent labels.43
■ CONCLUSIONS
HGD was chemically modified at two different amino acid
residues (Lys-2 and Cys-110) using PEGylated biotin. These
modified proteins were then used in mixtures with unmodified
HGD to assess what impact, if any, the presence of the
chemically modified protein had on solution behavior relative
to solutions containing unmodified protein alone. Both
mixtures containing a chemically modified protein (i.e. Lys
modified HGD and Cys modified HGD) showed an increase
in the net attraction of the system (as indicated by an increase
in Tph) relative to the unmodified protein, albeit to different
extents; mixtures containing HGD amine modified at Lys-2
with modified protein compositions of xm = 0.62 and 0.86 both
showed a slight increase in Tph (≤∼2 K), while mixtures
containing HGD thiol modified at Cys-110 with modified
protein compositions of xm = 0.47 and 0.89 showed a more
significant increase (≤∼10 K). These results are qualitatively
consistent with our previously published data using HGD
fluorescently labeled with a small molecule fluorescent label,
which showed that the protein modified at the Cys-110
position resulted in a much greater increase in Tph than the
protein modified at Lys-2. In this study, the width of the
liquid−liquid coexistence curve measured for each protein
mixture containing chemically modified and unmodified
protein was unchanged. This is in contrast with our previous
study using small molecule fluorescent dyes, where a decrease
in curve width was observed, which indicates an increase in the
range of the attraction. Complete phase separation of a sample
containing thiol modified HGD indicated that, as expected, the
majority of the chemically modified protein (that had a higher
net attraction than the unmodified protein) preferentially
partitioned into the dense protein phase. This observation is
consistent with previous studies using HGD and other proteins
with a higher net attraction. Near- and far-UV CD data
indicated that the increase in Tph of solutions containing the
chemically modified proteins is not as a result of a significant
structural change in either the secondary or tertiary structure
of the modified protein. These results are also consistent with
our previously published data using small molecule fluorescent
dyes.
Our results show that the effect of modifying the surface of a
protein on its solution behavior is not only highly dependent
on the physicochemical properties of the modifier used but
also on the site of the modification. This study has direct
industrial applicability given the widespread use of surface
Figure 4. Liquid−liquid coexistence curves for unmodified HGD
(black) and a mixture of unmodified HGD and HGD modified with
biotin (xm = 0.89). The diamonds indicate the volume fractions for
the dilute phase (ϕ = 0.06) and concentrated phase (ϕ = 0.38) after
liquid−liquid phase separation. The dashed line is a tie line and
connects the pair of volume fractions after phase separation. The
composition of biotinylated protein was 0.80 in the dilute phase and
0.87 in the dense phase.
Figure 5. (A) Near-UV and (B) far-UV circular dichroism spectra
showing unmodified HGD (black), amine modified HGD (blue), and
thiol modified HGD (pink).
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modifications, especially the use of Lys and Cys modifications,
in biotherapeutic innovation and development.
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